€0.46
Your prediction
Sangamo Therapeutics Inc. Stock
Pros and Cons of Sangamo Therapeutics Inc. in the next few years
Pros
Cons
Performance of Sangamo Therapeutics Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Sangamo Therapeutics Inc. | -1.670% | -5.095% | -28.145% | -67.855% | -15.789% | -94.998% | -95.431% |
Ardelyx Inc. | 0.910% | -5.482% | -15.972% | 32.578% | 3.218% | -12.905% | - |
Salarius Pharmaceuticals Inc. | 4.250% | -0.935% | -18.462% | -68.120% | -23.604% | -98.261% | -99.994% |
Brainstorm Cell | 1.170% | -0.896% | -1.485% | -81.710% | 114.440% | -80.717% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Sangamo Therapeutics, a company in the Biotechnology & Medical Research industry with the US symbol SGMO, has displayed a mixed financial performance over the past few years. The company's financial statements show some strengths and areas of concern. A detailed analysis of Sangamo Therapeutics' financials reveals the following pros and cons:
*Pros: *
Revenue Growth: Sangamo Therapeutics has experienced revenue growth over the last three periods, demonstrating its ability to generate higher sales. This is a positive sign for the company as it shows market demand for its products and services.
Comments
News
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 20 Sangamo abstracts for presentation at
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2023 financial results, including meaningful data